Logo image of CRTX

CORTEXYME INC (CRTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CRTX - US22053A1079 - Common Stock

1.95 USD
+0.05 (+2.63%)
Last: 7/29/2022, 8:00:01 PM
1.99 USD
+0.04 (+2.05%)
After Hours: 7/29/2022, 8:00:01 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CRTX. CRTX was compared to 533 industry peers in the Biotechnology industry. CRTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CRTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CRTX has reported negative net income.
CRTX Yearly Net Income VS EBIT VS OCF VS FCFCRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 -20M -40M -60M -80M

1.2 Ratios

Industry RankSector Rank
ROA -76.21%
ROE N/A
ROIC -65.97%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRTX Yearly ROA, ROE, ROICCRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 0 100 -100 200 300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRTX Yearly Profit, Operating, Gross MarginsCRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021

More info and screens

5

2. Health

2.1 Basic Checks

CRTX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
CRTX has more shares outstanding than it did 1 year ago.
There is no outstanding debt for CRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRTX Yearly Shares OutstandingCRTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 10M 20M 30M
CRTX Yearly Total Debt VS Total AssetsCRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 50M 100M 150M

2.2 Solvency

CRTX has an Altman-Z score of -1.13. This is a bad value and indicates that CRTX is not financially healthy and even has some risk of bankruptcy.
There is no outstanding debt for CRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.13
ROIC/WACC-6.96
WACC9.48%
CRTX Yearly LT Debt VS Equity VS FCFCRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 9.92 indicates that CRTX has no problem at all paying its short term obligations.
CRTX has a Quick Ratio of 9.92. This indicates that CRTX is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 9.92
Quick Ratio 9.92
CRTX Yearly Current Assets VS Current LiabilitesCRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

CRTX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.07%.
EPS 1Y (TTM)-6.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CRTX will show a small growth in Earnings Per Share. The EPS will grow by 4.39% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y20.5%
EPS Next 2Y15.85%
EPS Next 3Y10.42%
EPS Next 5Y4.39%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRTX Yearly EPS VS EstimatesCRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRTX Price Earnings VS Forward Price EarningsCRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.37
CRTX Per share dataCRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.85%
EPS Next 3Y10.42%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CORTEXYME INC

NASDAQ:CRTX (7/29/2022, 8:00:01 PM)

After market: 1.99 +0.04 (+2.05%)

1.95

+0.05 (+2.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-10 2022-05-10/amc
Earnings (Next)N/A N/A
Inst Owners17.23%
Inst Owner Change49.27%
Ins Owners33.57%
Ins Owner Change0%
Market Cap58.79M
Revenue(TTM)N/A
Net Income(TTM)-88.50M
Analysts45.45
Price Target22.7 (1064.1%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.55
P/tB N/A
EV/EBITDA 0.37
EPS(TTM)-2.97
EYN/A
EPS(NY)-1.99
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS3.53
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -76.21%
ROE N/A
ROCE N/A
ROIC -65.97%
ROICexc N/A
ROICexgc -65.97%
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.92
Quick Ratio 9.92
Altman-Z -1.13
F-Score4
WACC9.48%
ROIC/WACC-6.96
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
EPS Next Y20.5%
EPS Next 2Y15.85%
EPS Next 3Y10.42%
EPS Next 5Y4.39%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

CORTEXYME INC / CRTX FAQ

What is the ChartMill fundamental rating of CORTEXYME INC (CRTX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CRTX.


What is the valuation status for CRTX stock?

ChartMill assigns a valuation rating of 3 / 10 to CORTEXYME INC (CRTX). This can be considered as Overvalued.


What is the profitability of CRTX stock?

CORTEXYME INC (CRTX) has a profitability rating of 1 / 10.


What is the earnings growth outlook for CORTEXYME INC?

The Earnings per Share (EPS) of CORTEXYME INC (CRTX) is expected to grow by 20.5% in the next year.